Key facts
- Neurapex AI’s last known valuation is $1.3M (Jan 2026).
- It has raised $70K; the latest was Angel (individual) ($70K) in Jan 2026.
- Notable investors include Aman Gupta, Ritesh Agarwal.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Neurapex AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurapex AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurapex AI
Developer of a medtech platform designed to analyse magnetic resonance imaging scans, lab reports, medical images, and patient history to generate actionable reports. The company specializes in the detection of early alzheimer stages, neuro syndromes, and a wide range of complex problems, forecasting progression, treatments, and home remedies, enabling healthcare providers, hospitals, and diagnostic centers to improve early diagnosis and clinical decision-making.
- Sector
- Healthcare
- HQ
- Ghaziabad, India
- Founded
- 2025
- Website
- neurapex.in/
- Ownership
- Privately Held (backing)
Neurapex AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurapex AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurapex AI in its N-PORT filings yet. We sweep new filings monthly.